|
|
Article: New cancer weapon: Osteoporosis drug cuts breast cancer risk with fewer side effects than traditional medicine, study finds.
- Article from:
- Newsday (Melville, NY)
- Article date:
- April 18, 2006
CopyrightCOPYRIGHT 2006 Newsday. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Delthia Ricks
Apr. 18--A drug designed to prevent bone fractures lowered the risk of breast cancer just as well as the medication doctors have relied on for years - and with fewer side effects - in women whose chances of developing the disease are high. Raloxifene, an osteoporosis drug sold as Evista, reduced the risk of invasive breast cancer by 50 percent, just like tamoxifen, the most widely sold cancer drug in the world. Eight years ago scientists found that tamoxifen slashed the risk of breast cancer in half for healthy woman at high risk. But doctors say women have shied away from tamoxifen because of its potent side effects. Results from the ...
Related newspaper, magazine, and journal articles:
|
|
Article: Newer breast cancer drug has fewer side ...
Charleston Gazette;
April 18, 2006 ;
700+ words
... ... drug prevents breast cancer in older, high ... but with fewer side effects, the National ... developing invasive breast cancer, NCI announced ... caused the same side effects, but not as many ... years, and its breast cancer prevention benefit ... with no sign of ...
|
|